MedPath

Effect duloxetine versus amitriptyline on clinical outcomes of female with chronic pelvic pain syndrome

Phase 3
Recruiting
Conditions
Chronic pelvic pain syndrome.
Pelvic and perineal pain
R10.2
Registration Number
IRCT20120215009014N457
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
48
Inclusion Criteria

Age 18 to 50 years
Chronic pelvic pain syndrome for more than 6 months

Exclusion Criteria

Pregnancy or breastfeeding
Suffering from endometriosis, ovarian cyst, adenomyosis, fibroid or genital malignancy
Gastrointestinal diseases including irritable bowel syndrome or inflammatory bowel disease
History of previous hip surgery
Genitourinary infection
Cognitive or mental disorders
Kidney and liver dysfunction
History of alcohol and substance abuse

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of clinical symptoms (pain, difficulty in defecation). Timepoint: Before the intervention and one and two months after that. Method of measurement: Using the National Institutes of Health Chronic Syndrome Symptom Index (NIH-CSSI).;The rate of overall response to treatment. Timepoint: Two months after the intervention. Method of measurement: Using the Global Response Assessment (GRA) questionnaire.
Secondary Outcome Measures
NameTimeMethod
Occurrence of side effects (nausea, vomiting). Timepoint: one and two months after intervention. Method of measurement: With history taking.
© Copyright 2025. All Rights Reserved by MedPath